Continuation of personal insulin pump therapy during hospitalization may influence glycemic outcomes in adults with diabetes. A retrospective analysis presented at the AACE Annual Meeting 2026 evaluated inpatient glycemic control, length of stay, and safety outcomes with continuation versus discontinuation of outpatient insulin pump therapy.

The analysis was conducted within the Naples Comprehensive Healthcare System between November 2022 and November 2025. Of 79 identified patients using outpatient insulin pumps, 59 were included after exclusions. Patients were grouped based on whether pump therapy was continued (n=23) or discontinued (n=36) during hospitalization. Baseline characteristics, including age and body mass index (BMI), were similar between groups.

Pump continuation was associated with lower mean inpatient glucose levels (164.5 ± 46.8 vs 193.9 ± 52.4 mg/dL; P=0.030). Time in range (70-180 mg/dL) was higher (58.1% ± 26.8% vs 39.0% ± 23.7%; P=0.008). Time >250 mg/dL was lower (11.1% ± 17.8% vs 21.2% ± 19.8%; P=0.047). Time <70 mg/dL was low in both groups (0.84% vs 2.92%; P=0.094).

Length of stay was shorter with pump continuation (2.61 ± 1.47 vs 4.42 ± 3.73 days; P=0.012). Hypoglycemia events (4.3% vs 16.7%), 30-day readmissions, and emergency department visits (0% vs 13.9%) were numerically lower but not statistically significant.

The findings indicate that continuation of personal insulin pump therapy during hospitalization was associated with improved glycemic metrics and shorter length of stay in this cohort.